
Iovance Biotherapeutics Revenue | IOVA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Iovance Biotherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 264 M | 164 M | 1.19 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 264 M | 1.19 M | 143 M |
Quarterly Revenue Iovance Biotherapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 121 M | 99.3 M | 71.4 M | 86.8 M | 67.5 M | 60 M | 49.3 M | 73.7 M | 58.6 M | 31.1 M | 715 K | 482 K | 469 K | 238 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 121 M | 238 K | 51.5 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
8.01 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
455 K | - | - | $ 8.42 M | ||
|
Generation Bio Co.
GBIO
|
19.9 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
1.66 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
36.1 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
1.53 M | - | - | $ 2.36 B | ||
|
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M | ||
|
Galapagos NV
GLPG
|
1.11 B | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.1 M | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
1.4 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
2.04 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
5.06 M | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
1.5 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
2.05 M | - | - | $ 35.3 M | ||
|
Metacrine
MTCR
|
1.45 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
293 M | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
231 M | - | -0.04 % | $ 2.62 B | ||
|
Idera Pharmaceuticals
IDRA
|
4.86 M | - | -23.04 % | $ 26.6 M | ||
|
Verona Pharma plc
VRNA
|
42.3 M | - | - | $ 69.7 B | ||
|
Guardion Health Sciences
GHSI
|
12.2 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
47.8 M | - | - | $ 109 M | ||
|
ImmunoGen
IMGN
|
109 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
310 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
1.28 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
37 K | - | - | $ 591 K | ||
|
Navidea Biopharmaceuticals
NAVB
|
65.7 K | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
21.1 M | - | - | $ 23.9 M | ||
|
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
83.8 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
18 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
43.1 M | - | - | $ 35.4 M | ||
|
Sigilon Therapeutics
SGTX
|
12.9 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
10 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
4.42 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
7.7 M | $ 84.95 | 0.13 % | $ 7.99 B |